Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP3 | Q9NY33 | 5/20 | 0.58 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.49 |
| ▸ | CTSB | P07858 | 2/20 | 0.49 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.49 |
| ▸ | CCKBR | P32239 | 6/20 | 0.48 |
| ▸ | TACR1 | P25103 | 1/20 | 0.48 |
| ▸ | REN | P00797 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10036419 | 0.92 | DPP3 (0.60) | DPP3CAPN1CTSBKISS1RTACR1 | |
| SCHEMBL13018973 | 0.82 | DPP3 (0.55) | DPP3CAPN1CTSBKISS1RCCKBR | |
| SCHEMBL13950953 | 0.82 | DPP3 (0.55) | DPP3CAPN1CTSBKISS1RCCKBR | |
| SCHEMBL24245857 | 0.82 | DPP3 (0.54) | DPP3CAPN1CTSBTACR1 | |
| SCHEMBL10036420 | 0.82 | DPP3 (0.48) | DPP3CAPN1CTSBKISS1RTACR1 | |
| SCHEMBL29572021 | 0.81 | DPP3 (0.71) | DPP3TACR1REN | |
| SCHEMBL22753494 | 0.79 | DPP3 (0.51) | DPP3CAPN1CTSBCCKBR | |
| SCHEMBL30610091 | 0.78 | DPP3 (0.69) | DPP3 | |
| SCHEMBL29648960 | 0.78 | DPP3 (0.69) | DPP3 | |
| SCHEMBL29993706 | 0.77 | DPP3 (0.68) | DPP3REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2271665-B1 | HIGHLY BRIDGED PEPTIDES FROM ACTINOMADURA NAMIBIENSIS | SANOFI SA (FR) | 2012-01-18 | — | — | EP | disclosed |
| US-20110144001-A1 | HIGHLY BRIDGED PEPTIDES FROM ACTINOMADURA NAMIBIENSIS | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | disclosed |
| US-20110144001-A1 | HIGHLY BRIDGED PEPTIDES FROM ACTINOMADURA NAMIBIENSIS | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | disclosed |
| WO-2009121483-A1 | HIGHLY BRIDGED PEPTIDES FROM ACTINOMADURA NAMIBIENSIS | SANOFI-AVENTIS (FR) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144001-A1 | HIGHLY BRIDGED PEPTIDES FROM ACTINOMADURA NAMIBIENSIS | HM13, VIP, NPBWR1 | DPP3 1697/4885CAPN1 2286/4885CTSB 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.